… KRAS G12C activation and inhibitor engagement, we found that an SHP2 inhibitor (SHP2-I)
increases KRAS-GDP occupancy, enhancing G12C-I efficacy. The SHP2-I abrogated RTK …

… of SHP2 in cancer and the tumor microenvironment, and the clinical strategies in which SHP2
inhibitors … and growth in the remodeling of tumor vasculature; SHP2 inhibition by SHP099, …

… selective allosteric inhibitor of SHP2, RMC-… SHP2 inhibition in vivo in the tumor
microenvironment. Using syngeneic mouse tumor models, we reveal an unanticipated impact of …

… remodeling tumor vasculature. Using genetic and chemical approaches to inhibit SHP2 activity
in endothelial cells, we show that SHP2 … Systemic SHP2 inhibition in mice bearing tumor …

… of cancer therapeutics requires delineation of tumor cell-… Here, we report the effects of
G12C-I, SHP2-I, and G12C-I/SHP2… -I/SHP2-I efficacy derives from effects on tumor cells and …

… SHP2 inhibitors, as well as their potential role in immune signaling modulation as a promising
cancer-… They are key regulators of tissue homeostasis and tumor microenvironments [51]. …

… in tumor microenvironment. A few clinical trials conducted using SHP2 allosteric inhibitors
have shown remarkable anti-tumor … , angiogenesis, matrix remodeling, and metastasis, making …

… mutants and provide new evidence that combination therapy affects the tumor microenvironment
(angiogenesis and stroma), can, at least in some models, promote differentiation of …

… to explore the role of SHP2 in all cell types of tumor microenvironment (TME) from murine …
to SHP099, a SHP2 allosteric inhibitor. The malignant evolution of tumor cells was remarkably …

… neo-angiogenesis, stroma remodeling, and … Shp2 inhibitor will inactivate Shp2 both in tumor
cells and stroma cells. However, in contrast to the extensively studied roles of Shp2 in tumor …